References
- Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005;127:1219-26 https://doi.org/10.1378/chest.127.4.1219
- Hurst JR, Perera WR, Wilkinson TM, Donaldson GC. Wedzicha JA. Systemic and upper and lower airway inflannnation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-8 https://doi.org/10.1164/rccm.200505-704OC
- Donaldson GC, Seernunga] TA, Patel IS, Bhowrnik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflannnation and decline in lung function in patients With COPD. Chest 2005;128:1995-2004 https://doi.org/10.1378/chest.128.4.1995
- Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD. Chest 2004;126:926-34 https://doi.org/10.1378/chest.126.3.926
- Wouters EF. l.ocal and systemic inflannnation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:26-33
- Buffels J, Degryse J, Heyrman J, DecrarnerM Office spirometry significantly improves early detection of COPD in general practice. Chest 2004;125:1394-9 https://doi.org/10.1378/chest.125.4.1394
- Dales RE, Vandembeen Kl., Clinch J, Aaron SD. Spirometry in the primary care setting: influence on clinical diagnosis and management of airflow obstruction. Chest 2005;128:2443-7 https://doi.org/10.1378/chest.128.4.2443
- Zielinski J, Bednarek M Early detection in a high-risk population using spirometric screenig. Chest 2001;119:731-6 https://doi.org/10.1378/chest.119.3.731
- Bolton CE, Ionescu M, Edwards PH, Faulkner TA, Edwards SM, Shale DJ. Attaining a correct diagnosis of COPD in general practice. Respir Med 2005; 99;493-500 https://doi.org/10.1016/j.rmed.2004.09.015
- O'Donnell DE, Fluge T, Gerken F, Hamiltexercise on A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and tolerance in COPD. Eur Respoir J 2004;23;832-40 https://doi.org/10.1183/09031936.04.00116004
- Verkindre C, Bart F, Aguilaniu B, Fortin F, Guerin JC, Ie Merre C, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73;420-7 https://doi.org/10.1159/000089655
- Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128;1168-78 https://doi.org/10.1378/chest.128.3.1168
- van Noord JA, Aumann 11., Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26;214-22 https://doi.org/10.1183/09031936.05.00140404
- van Noord JA, Aumann JL, Janssens E, Vehaert J, Smeets JJ, Mueller A, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129;509-17 https://doi.org/10.1378/chest.129.3.509
- WIlkinson TM, Donaldson GC, Hurst JR, SeemnngaJ TA, Wedzicha JA. Early therapy improves outcomes of exacervations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169; 1298-303. https://doi.org/10.1164/rccm.200310-1443OC
- Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005;26;420-8 https://doi.org/10.1183/09031936.05.00136304
- Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172;1510-6 https://doi.org/10.1164/rccm.200504-595OC
- Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr. Korducki 1., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med 2005;143;317-26 https://doi.org/10.7326/0003-4819-143-5-200509060-00007
- Dusser D, Bravo Ml., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;27;547-55 https://doi.org/10.1183/09031936.06.00062705
- Celli BR. Chronic obstructive pulmonary disease from unjustified nihilism to evidence-based optimism Proc Am Thorac Soc 2006;3;58-65
- Buist S. COPD; a common disease that is preventable and treatable. Prim Care Rsepir J 2006;15;7-9 https://doi.org/10.1016/j.pcrj.2005.12.004
- Anzueto A, TashkinD, MeJ1ioge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium .Pulm Pharmacal Ther 2005;18;75-81 https://doi.org/10.1016/j.pupt.2004.10.003
- Barnes PJ, Stockley RA. COPD; current therapeutic interventions and future approaches. Eur Respir J 2005;25;1084-106 https://doi.org/10.1183/09031936.05.00139104
- Wilson R. Treatment of COPD exacerbations; antibiotics. Eur Respir Rev 2005;14;32-8 https://doi.org/10.1183/09058180.05.00009404
- Beading C, Slifka MK. How do viral infections predispose patients to bacterial infections- Curr Opin Infect Dis 2004;17;185-91 https://doi.org/10.1097/00001432-200406000-00003
- Wikinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006;129;317-24 https://doi.org/10.1378/chest.129.2.317
- Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106;196-204 https://doi.org/10.7326/0003-4819-106-2-196
- van der Valk P, Monninkbof E, van der Palen J, Zielhuis G, van Herwaarden C, Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2004;39;980-6 https://doi.org/10.1086/423959
- Rosell A, Manso E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005;165;891-7 https://doi.org/10.1001/archinte.165.8.891
- Wilson R Treatment of COPD exacerbations; antibiotics. Eur Respir Rev 2005;14;32-8 https://doi.org/10.1183/09058180.05.00009404
- Sethi S. Bacteria in exacerbations of chronic obstructive puhnonary disease. Proc Am Thorac Soc 2004;1;109-14
- Wilson R, Schentag JJ, Ball P, Mandell L.. A comparison of gemifloxacin and drithromycin in acute exacerbations of chronic bronchitis and lung-term clinical outcomes. Clin Ther 2002;24;639-52 https://doi.org/10.1016/S0149-2918(02)85139-6
- Wilson R, Allegra L., Huchon G, Izquierdo JL., Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxcin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125;953-64 https://doi.org/10.1378/chest.125.3.953
- Martinez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbation of chronic bronchitis. Am J Med 2005;118(Suppl 7A);39S-44S https://doi.org/10.1016/j.amjmed.2005.05.012
- Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-7 https://doi.org/10.1164/rccm.200407-867OC
- Celli BR Cote CG, Marin J, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350;1005-12 https://doi.org/10.1056/NEJMoa021322
- Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE Index) as predictor of hospitalization for COPD. Chest 2005;128;3810-6 https://doi.org/10.1378/chest.128.6.3810
- Cote CG, Celli BR Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005;26;630-6 https://doi.org/10.1183/09031936.05.00045505